Health Insurer Recommends RSV Prevention for Infants - RSV Cases Surge in Germany, Threatening Infants and Elderly in 2024

Respiratory syncytial virus (RSV) remains a serious health risk, particularly for infants and older adults. The infection can lead to severe lower respiratory diseases, sometimes requiring mechanical ventilation. Recent data from health insurer IKK Südwest highlights the virus's impact in three German states during 2024.

RSV spreads through droplets and poses the greatest danger to vulnerable age groups. Infants often face severe complications in their first season of exposure. For this reason, health authorities recommend nirsevimab, a preventive treatment, for babies during their initial RSV season. Older adults, particularly those aged 75 and above, are also advised to receive the RSV vaccination.

IKK Südwest, which insures around 600,000 people across Rhineland-Palatinate, Hesse, and Saarland, reported roughly 700 RSV cases among insured infants in these regions last year. While nationwide figures for 2024 remain unclear, general estimates suggest about 25,000 severe infant cases per season. Prophylaxis measures in 2024/25 reportedly halved these numbers, though specific data for older adults or states like Bavaria—where cases rose in 2026—is not available.

The figures underscore RSV's persistent threat, especially to the very young and elderly. Preventive treatments and vaccinations have already shown results in reducing severe cases. Health officials continue to monitor trends as new data emerges.